Drug · DIN 02280213
AVALIDE
No: no longer authorized
The company stopped selling it and its DIN was cancelled. A cancellation is most often a business decision; the record does not say why.
Status Cancelled Post Market since July 17, 2017; first marketed May 19, 2006.
- Drug Identification Number (DIN)
- 02280213
- Company (DIN owner)
- Sanofi-Aventis Canada Inc.Toronto, Ontario, Canada
- Schedule
- Prescription
- Dosage form
- Tablet
- Route
- Oral
- Therapeutic class (ATC)
- Irbesartan and diuretics C09DA04
- Class
- Human
- Record last updated
- June 26, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| IRBESARTAN | 300 MG | |
| HYDROCHLOROTHIAZIDE | 25 MG |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 12, 2006: NOC 7958Supplement to a New Drug Submission (SNDS) · New strength 300/25 mg (irbesartan/hydrochlorothiazide)
Recalls and safety alerts that mention it
Health Canada’s recall notices do not carry licence numbers, so these are matched by name: notices whose title or product names “avalide”. A notice may cover another product or only some lots: read it to see what it covers.
- Sanofi-Aventis Avalide Product Recall(2021-06-14)June 14, 2021 · Drugs · Product safety · Type I
Other DINs named AVALIDE
- DIN 02241818 · Marketed
- DIN 02241819 · Marketed